GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
An Imaging Study to Investigate the Distribution of GW842166X in the Brain.
- Conditions
- Pain, Inflammatory
- Interventions
- Drug: GW842166XDrug: [carbonyl-^11C]GW842166
- First Posted Date
- 2007-08-06
- Last Posted Date
- 2017-08-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6
- Registration Number
- NCT00511524
- Locations
- 🇸🇪
GSK Investigational Site, Uppsala, Sweden
28-day Repeat Dose and Drug Interaction Study With Orvepitant (GW823296)
- Conditions
- Depressive Disorder
- Interventions
- First Posted Date
- 2007-08-06
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT00511654
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults
- Conditions
- Influenza
- Interventions
- Biological: Pandemrix ™Biological: Pumarix™
- First Posted Date
- 2007-08-02
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 780
- Registration Number
- NCT00510874
- Locations
- 🇨🇦
GSK Investigational Site, Sherbrooke, Quebec, Canada
Evaluation of Potential for Orthostatic Hypotension in Elderly Hypertensives
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2007-07-30
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 62
- Registration Number
- NCT00508365
- Locations
- 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States
A Study To Evaluate The Effects Of Repeat Dosing Of Esomeprazole On The Pharmacokinetics Of SB-751689 In Healthy People
- Conditions
- Osteoporosis
- First Posted Date
- 2007-07-30
- Last Posted Date
- 2009-05-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 13
- Registration Number
- NCT00508534
- Locations
- 🇸🇬
GSK Investigational Site, Singapore, Singapore
Safety and Efficacy of SmithKline Beecham (GlaxoSmithKline [GSK]) Biologicals' Candidate Adjuvanted Vaccines (287615)
- Conditions
- Hepatitis B Disease
- First Posted Date
- 2007-07-30
- Last Posted Date
- 2007-07-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 200
- Registration Number
- NCT00508833
- Locations
- 🇧🇪
GSK Clinical Trials Call Center, Gent, Belgium
A Study To Evaluate The Effect Of GW876008 On The Pharmacokinetics Of Oral Contraceptive Pills
- First Posted Date
- 2007-07-30
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 4
- Registration Number
- NCT00508911
- Locations
- 🇬🇧
GSK Investigational Site, Harrow, Middlesex, United Kingdom
Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine
- Conditions
- Infections, Meningococcal
- Interventions
- Biological: Meningococcal vaccine GSK134612Biological: Meningitec™Biological: Infanrix™ hexa
- First Posted Date
- 2007-07-27
- Last Posted Date
- 2019-01-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 793
- Registration Number
- NCT00508261
- Locations
- 🇬🇷
GSK Investigational Site, Veria, Greece
Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults
- Conditions
- Influenza
- Interventions
- Biological: Pandemic influenza candidate vaccine (GSK1562902A) - 2 dosesBiological: Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2017-10-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 350
- Registration Number
- NCT00506350
- Locations
- 🇧🇪
GSK Investigational Site, Gent, Belgium
A Phase III, Open-Label, Single-Dose Study to Evaluate the Safety and Immunogenicity of Fluviral® Vaccine
- Conditions
- Influenza
- First Posted Date
- 2007-07-23
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 110
- Registration Number
- NCT00505453
- Locations
- 🇨🇦
GSK Investigational Site, Quebec, Canada